The trial participants will have been constrained during the trial to opt for alternative treatments.
With the conclusion of the Anavax trial, that constraint should be lifted, and the trial participants should be able to have access to NEU's Trofinetide, with its demonstrable patient benefits.
- Forums
- ASX - By Stock
- NEU
- ANAVEX MEETS ENDPOINTS PHASE2 RETT
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-99
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.32 |
Change
-0.240(1.54%) |
Mkt cap ! $1.958B |
Open | High | Low | Value | Volume |
$15.61 | $15.93 | $14.96 | $8.851M | 580.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 6444 | $15.18 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.33 | 2341 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 6444 | 15.180 |
2 | 3927 | 15.150 |
1 | 2341 | 15.120 |
1 | 2341 | 15.090 |
1 | 1000 | 15.050 |
Price($) | Vol. | No. |
---|---|---|
15.330 | 2341 | 1 |
15.360 | 2341 | 1 |
15.380 | 2341 | 1 |
15.410 | 2341 | 1 |
15.500 | 7600 | 2 |
Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online